PRIMARY STUDY

Cannabinoid Receptor 2 (CB2) Inverse Agonist SMM-189 Induces Expression of Endogenous CB2 and Protein Kinase A That Differentially Modulates the Immune Response and Suppresses Experimental Colitis

Key Findings:  Resulting data found that the CB2 inverse agonist SMM-189 was able to reverse colitis-associated pathogenesis, increased expression of CB2 receptor sites, increased myeloid-derived suppressor cells, increase body weight and colon length in the test animals. As such the authors suggest that SMM-189 may have therapeutic efficacy in experimental colitis by inducing the expression of CB2 and protein kinase A in colon lamina propria lymphocytes.